Medical Advances Contribute to Growth of Global Biological Drugs Market

  • Published On : Dec 09, 2014
Biological drugs are manufactured by extracting cells from other living organisms such as animals and plants. These drugs differ from conventional drugs in many complex ways. Most of the biological drugs are large and are made using complex molecules or mixtures of certain molecules. Many a time, recombinant DNA technology is also used to make these drugs. Each biological drug is a process in itself as the finished drug cannot be reproduced in a laboratory. On a average, a biological drug has to go through 250 in-process laboratory tests as compared to mere 50 tests for a conventional drug.

The global biological drugs market has seen a stupendous leap in the past few years with huge investment in research and development. Unfortunately, the biological drugs cannot attain the stature of generic drugs as producing them on a large scale is a near-to-impossible task due to the sensitive nature of the living organisms used in the processes. A minor change in the environment can severely and adversely affect the final output of the biological drug. In a hypothetical case for manufacturers to produce biological drugs, they will have to ensure the production happens in a tightly controlled environment with standard procedures of extracting raw materials to achieve predictable manufacturing output.

Market Division of Global Biological Drugs Market

The global biological drug market has been segmented on the basis of protein, monoclonal antibody (mAb) mAb, vaccine, and geography. The protein segment of global biological drugs market is inclusive of Enbrel 30, Lantus 33, Neulasta 35, Avonex 37, NovoLog 40, Rebif 42, Humalog 44, Aranesp 46, Epogen 48, Levemir 50, Victoza 52, Betaseron 54, Neupogen 56, and Eylea 58. The mAb segment consists of Humira 60, Remicade 63, Rituxan 65, Avastin 67, Herceptin 70, and Lucentis 72. Furthermore, the vaccine segment in the global biological drugs market contains, Prenvar 13 74, Gardasil 77, Fluzone 79, Varivax 81, and Cervarix 83. Finally, in terms of geography the global biological market has been bi-furcated on the basis of regions such as North America, Europe, Asia Pacific, and Rest of the World.

Future of Global Biological Drugs Market

The global biological drugs market was valued at US$1, 61,056.5 million in 2014, and is expected to reach US$2, 87,139.7 million by 2020, growing at a CAGR of 10.1% from 2014 to 2020. In this span of six long years, the global biological drug market will be driven by increasing geriatric population, rising incidences of chronic illnesses, and growing number of cases of cancer. As these numbers are only likely to rise, they will aggressively fuel the global biological drugs market. The primary use of biological drugs is seen in prevention of diseases such as those related to blood, auto-immune diseases, and other complex medical disorders.

The other factor contributing to a great extent to the rise of global biological drugs market is the increased government spending on their research, development, and promotion of these drugs. With the support from government bodies, many companies are now able to develop better drugs. In addition to this, as the field of biomedical science is also witnessing noteworthy advancements, it is creating a huge potential for growth of global biological drugs market. 

According to analysts, North America holds the biggest market share for biological drugs, while Enbrel is the fastest and largest growing therapeutic protein. In the vaccine segment, Prevnar 13 is the largest and fastest growing vaccine, while in the monoclonal antibody (mAb) segment, Humira is the largest and fastest growing mAb. Some of the key players making a difference in the global biological drugs market are GlaxoSmithKline plc, Bristol-Myers Squibb Company, Abbott Laboratories, Pfizer Inc., Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec.  Over the years, the key growth strategies of these companies, the decisions of policy makers in several economies, and the advances in medical science will decide the future of global biological drugs market and thereby the future of the world economy.

Browse Full Global Biological Drugs Market Research Report With Complete TOC @
Back To Top